614 McKinley Place N.E.
138 articles with Bio-Techne
Bio-Techne has entered into a strategic cooperation agreement with Micropoint Bioscience of Shenzhen, China.
Bio-Techne is proud to announce that one of its Principal Scientists, Jiaqi Wu, Ph.D., was presented with the CE Pharm Award at this year's CE Pharm meeting, September 9-12, 2018, for his contributions to the capillary electrophoresis (CE) field.
Bio-Techne has announced a corporate initiative to advance cell and gene therapy research and ex vivo cell processing.
Bio-Techne Announces Publication of Data Demonstrating Additional Clinical Validation of its EPI Test in European Urology Journal
Bio-Techne today announced the online publication of its second prospective US clinical validation study of the Exosome Diagnostics-branded ExoDx® Prostate(IntelliScore) (EPI)
Bio-Techne researchers publish papers that promise to open the field of glycobiology to the masses.
Bio-Techne Corporation today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018, at 8:00 a.m. EDT.
Bio-Techne Corporation today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Baird 2018 Global Healthcare Conference on Thursday, September 6, 2018, at 9:40 a.m. EDT.
Bio-Techne has introduced a new range of Tocris Bioscience-branded stem cell research compounds produced to cGMP standards, which are suitable for use as ancillary materials in the development of stem cell therapies.
Bio-Techne Corporation reported its financial results for the fourth quarter ended June 30, 2018.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2018.
Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its acquisition of Exosome Diagnostics, Inc.
Bio-Techne again disrupts protein analysis technology with the introduction of the newest member of their ProteinSimple-branded Simple Western family, Jess.
Bio-Techne To Host Conference Call On August 7, 2018 To Announce Fourth Quarter 2018 Financial Results
Bio-Techne Corporation announced that management will host a conference call on Tuesday, August 7, 2018 at 8:00 a.m. CDT to review fourth quarter 2018 financial results.
Bio-Techne Scales Antibody Validation Initiative Using CRISPR Gene Editing Technology Across a Broad Spectrum of Targets
Knockout Validation of Antibodies Confirms Specificity and Ensures Reproducible Results
Validated tissue bank and pre-collected immuno-oncology datasets speed up investigative research projects through to clinical development...
The transaction is expected to close in early July and to be financed through available cash on hand.
Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the William Blair 38th Annual Growth Stock Conference.
Bio-Techne Corporation reported its financial results for the third quarter ended March 31, 2018.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2018.
Bio-Techne has a leading role supporting autophagy research.